MedPath

The efficacy and safety of picosecond 1064 nm Nd:YAG laser in treatment of post sclerotherapy hyperpigmentation: a pilot study.

Phase 1
Completed
Conditions
post sclerotherapy hyperpigmentationthe complication of cosmetic sclerotherapy safety profile of using picosecond 1064 nm Nd:YAG laser in low-fluence non-ablative setting
sclerotherapy
hyperpigmentation
laser
sclerotherapy adverse effects
Registration Number
TCTR20210507005
Lead Sponsor
Institute of Dermatology, Thailand
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
12
Inclusion Criteria

1. Patient is diagnosed as post-sclerotherapy hyperpigmentation from sclerotherapy using 0.1- 1% polidocanol in liquid or foam solution. Off- treatment time is 3-months period.
2. No truncal reflux by Duplex ultrasound study.
3. The patient has 2 lesions or more.
4. Those lesions has similar melanin index.
5. Age > 18 years.
6. Fitzpatrick skin type III-V
7. Patient could make a visit as appointed
8. Patient has no history of using bleaching agents such as hydroquinone, retinoids prior to the study.

Exclusion Criteria

1. Patient is receiving anticoagulant, minocycline or iron supplements.
2. Patient has received laser treatment on the study sites within 6 months.
3. Pregnant patient
4. Patient with history of photosensitive conditions
5. Patient with history or risk of keloidal scar formation

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mean melanin index at 4 weeks and 8 weeks after the intervention Mexameter
Secondary Outcome Measures
NameTimeMethod
Patient satisfactory score 4 weeks after the intervention Patient reported outcome using a 5-point rating scale questionnaire.,Physician evaluation score 4 weeks after the intervention Physician reported outcome using a 5-point rating scale questionnaire.
© Copyright 2025. All Rights Reserved by MedPath